Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 1

1(14.3%)

Phase 3

1(14.3%)

7Total

Phase 2(5)

Phase 1(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07364786Phase 2Recruiting

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma

Role: lead

NCT04117672Phase 2Recruiting

Antisecretory Factor In Severe Traumatic Brain Injury

Role: lead

NCT05669820Phase 2Recruiting

Antisecretory Factor Glioblastoma Phase 2

Role: lead

NCT06710249Phase 2Recruiting

Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema

Role: lead

NCT03339505Phase 3Completed

Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury

Role: lead

NCT04116138Phase 1Completed

Antisecretory Factor in Primary Glioblastoma 1

Role: lead

NCT03453749Phase 2Withdrawn

Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury

Role: lead

All 7 trials loaded